1) Clinical, biochemical and genetic aspects of patients suffering from a pyrimidine degradation defect.

2) Pharmacogenetic aspects associated with inborn errors of purine and pyrimidine metabolism

3) Pre-clinical screening of drug combinations for neuroblastoma. Optimising current treatment modalities through targeting the PI3K/Akt pathway.

4) Catecholamine excretion in neuroblastoma: identification of catecholamine metabolites profiles associated with clinical and genetic characteristics of neuroblastoma

Theme: Metabolic Disorders and Oncology

This research group participates in the Amsterdam Center for Metabolism
Effective start/end date01/06/2016 → …

ID: 178135